lamivudine has been researched along with gsk1265744 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Angel, JB; Clair, MS; Clotet, B; Crauwels, H; Dorey, D; Eron, JJ; Ford, SL; Gonzalez-Garcia, J; Griffith, SK; Gutierrez, F; Lutz, T; Margolis, DA; Mrus, J; Murray, M; Patel, P; Podzamczer, D; Richmond, GJ; Sloan, L; Smith, KY; Spreen, WR; Stellbrink, HJ; Sutton, KC; Williams, PE; Yazdanpanah, Y | 1 |
| Amole, C; Jenkins, SY; Panos, Z; Resar, D; Ripin, D; Staple, A; Watkins, M | 1 |
1 trial(s) available for lamivudine and gsk1265744
| Article | Year |
|---|---|
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Female; Global Health; HIV Infections; HIV-1; Humans; Injections, Intramuscular; Lamivudine; Male; Pyridones; Reverse Transcriptase Inhibitors; Rilpivirine; Viral Load | 2017 |
2 other study(ies) available for lamivudine and gsk1265744
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Securing accelerated access to long-acting injectable cabotegravir for HIV prevention in low- and middle-income countries.
Topics: Child; Developing Countries; Drugs, Generic; HIV Infections; Humans; Lamivudine; Tenofovir; United States | 2023 |